Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 19

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
763 Exercise of stock options585 10,374 — — — 10,374 Issuance of common stock, net of transaction costs929 48,296 — — — 48,296 Issuance of common stock upon vesting of restricted stock units5 — — — — — Stock-based compensation— 18,147 — — — 18,147 Other comprehensive income— — 2,228 — — 2,228 Net loss— — — (76,828)— (76,828)Balance at September 30, 202480,841 $1,702,457 $2,038 $(871,515)$— $832,980 Balance on January 1, 202468,175 $1,191,831 $977 $(653,702)$— $539,106 Issuance of common stock, net of transaction costs10,486 427,200 — — — 427,200 Exercise of stock options1,816 30,858 — — — 30,858 Stock issued under Employee Stock Purchase Plan115 2,027 — — — 2,027 Issuance of common stock upon vesting of restricted stock units249 — — — — — Stock-based compensation— 50,541 — — — 50,541 Other comprehensive income— — 1,061 — — 1,061 Net loss— — — (217,813)— (217,813)Balance at September 30, 202480,841 $1,702,457 $2,038 $(871,515)$— $832,980 

See the accompanying notes to these unaudited condensed consolidated financial statements.

5

Table of Contents

Crinetics Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

Nine months endedSeptember 30,20252024CASH FLOWS FROM OPERATING ACTIVITIESNet loss$(342,502)$(217,813)Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation69,304 50,541 Depreciation and amortization2,896 1,997 Noncash